JP2018506549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506549A5 JP2018506549A5 JP2017542862A JP2017542862A JP2018506549A5 JP 2018506549 A5 JP2018506549 A5 JP 2018506549A5 JP 2017542862 A JP2017542862 A JP 2017542862A JP 2017542862 A JP2017542862 A JP 2017542862A JP 2018506549 A5 JP2018506549 A5 JP 2018506549A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- combination
- indazol
- dihydropyridine
- yloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- -1 3-fluoro-4- (1-methyl-6- (1H-pyrazol-4-yl) -1H-indazol-5-yloxy) phenyl Chemical group 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960002633 ramucirumab Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- KCNQARIQPHGIDQ-UHFFFAOYSA-N 6-methyl-2-oxo-1h-pyridine-3-carboxamide Chemical compound CC1=CC=C(C(N)=O)C(=O)N1 KCNQARIQPHGIDQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- QHADVLVFMKEIIP-UHFFFAOYSA-N n-[3-fluoro-4-[1-methyl-6-(1h-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide Chemical compound O=C1N(C=2C=CC(F)=CC=2)C(C)=CC=C1C(=O)NC(C=C1F)=CC=C1OC1=CC=2C=NN(C)C=2C=C1C=1C=NNC=1 QHADVLVFMKEIIP-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204088P | 2015-08-12 | 2015-08-12 | |
| US62/204,088 | 2015-08-12 | ||
| PCT/US2016/046259 WO2017027544A1 (en) | 2015-08-12 | 2016-08-10 | Combination therapy for cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506549A JP2018506549A (ja) | 2018-03-08 |
| JP2018506549A5 true JP2018506549A5 (enExample) | 2018-06-07 |
| JP6351864B2 JP6351864B2 (ja) | 2018-07-04 |
Family
ID=56787691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542862A Expired - Fee Related JP6351864B2 (ja) | 2015-08-12 | 2016-08-10 | 癌の併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180207268A1 (enExample) |
| EP (1) | EP3334458A1 (enExample) |
| JP (1) | JP6351864B2 (enExample) |
| CN (1) | CN108136004A (enExample) |
| MA (1) | MA42609A (enExample) |
| TW (1) | TW201716085A (enExample) |
| WO (1) | WO2017027544A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190336599A1 (en) * | 2016-04-15 | 2019-11-07 | Eli Lilly And Company | Combination of ramucirumab and merestinib for use in treatment of colorectal cancer |
| CN112739691B (zh) * | 2018-09-03 | 2023-05-23 | 泰励生物科技（上海）有限公司 | 用作抗癌药的trk抑制剂 |
| CN110721183A (zh) * | 2019-11-15 | 2020-01-24 | 四川大学 | Met和axl双靶点抑制剂在制备防治胃癌的药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI365185B (en) * | 2008-07-24 | 2012-06-01 | Lilly Co Eli | Amidophenoxyindazoles useful as inhibitors of c-met |
| CN202105462U (zh) * | 2011-06-16 | 2012-01-11 | 保靖天瑞钒业有限公司 | 一种搅拌桨 |
| TW201622744A (zh) * | 2014-03-04 | 2016-07-01 | 美國禮來大藥廠 | 癌症之組合療法 |
-
2016
- 2016-07-27 TW TW105123795A patent/TW201716085A/zh unknown
- 2016-08-10 WO PCT/US2016/046259 patent/WO2017027544A1/en not_active Ceased
- 2016-08-10 US US15/745,451 patent/US20180207268A1/en not_active Abandoned
- 2016-08-10 MA MA042609A patent/MA42609A/fr unknown
- 2016-08-10 JP JP2017542862A patent/JP6351864B2/ja not_active Expired - Fee Related
- 2016-08-10 CN CN201680046752.9A patent/CN108136004A/zh active Pending
- 2016-08-10 EP EP16754601.9A patent/EP3334458A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501848A5 (enExample) | ||
| JP2018127467A5 (enExample) | ||
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2020500181A5 (enExample) | ||
| JP2018184417A5 (enExample) | ||
| JP2018506550A5 (enExample) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| JP2016528247A5 (enExample) | ||
| JP2012102122A5 (enExample) | ||
| RU2015112576A (ru) | Комбинированная терапия с использованием антитела против cd20 типа ii и селективного ингибитора bcl-2 | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| JP2016530280A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| EA201691375A1 (ru) | (2s)-n-[(1s)-1-циано-2-фенилэтил]-1,4-оксазепан-2-карбоксамиды в качестве ингибиторов дипептидилпептидазы i | |
| JP2015505564A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| TW201307392A (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| JP2017537105A5 (enExample) | ||
| JP2016523260A5 (enExample) | ||
| RU2016151757A (ru) | Антагонисты pdl-1 и pd-1 для лечения hpv-отрицательных форм рака | |
| MX2018015353A (es) | Usos terapeuticos de un inhibidor de c-raf. | |
| JP2019517549A5 (enExample) | ||
| JP2015525798A5 (enExample) |